reports
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial...
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live ...
Royalty Pharma to Highlight Accomplishments and Provide Business Updat...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including pivotal data readouts for daraxonrasib, litifilimab and pelacarsen NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its b...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of P...
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently in Phase 1b for treatment of vitiligo and in Phase 2a for celiac diseaseFunding agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and bring treatments to patients faster NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -...
Royalty Pharma Announces Dividend Increase
Royalty Pharma Announces Dividend Increase NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 20, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leadi...
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi ...
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020 NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired the final portion of PTC Therapeutics’ remaining royalty on Roche’s Evrysdi for $240 million upfront and up to $60 million in sales-based milestones. Evrysdi, marketed by Roche, is an orally administered survival motor neuron-2 (SMN2) splicing mod...
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and ...
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs). Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer (NSCLC) and zidesamtinib is in development for ROS1 mutation-pos...
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty F...
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicleTM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). A Biologics License Application (BLA) for accelerat...
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: Citi’s 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ETEvercore’s 8th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 199...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
Royalty Pharma Reports Third Quarter 2025 Results
Royalty Pharma Reports Third Quarter 2025 Results Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $703 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered strong third quarter 2025 results, raised our full year guidance and are on track to deliver another ...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $31...
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from , in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial. AMVUTTRA is an FDA-approved RNAi therapeutic for the treatment of ATTR amyloidosis, a progressive, ...
Royalty Pharma Declares Fourth Quarter 2025 Dividend
Royalty Pharma Declares Fourth Quarter 2025 Dividend NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovato...
Royalty Pharma to Announce Third Quarter 2025 Financial Results on Nov...
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the confere...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Downgrading Financials to Underweight We remain bullish since our 4/22/25 Compass, and we will maintain our bullish outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6028-6059. We would need to see a break below 6569 in order to have confidence that a consolidation period has finally begun. For now, we continue to expect support to show up at the 4-month uptrend, which generally coincides with the 20-day MA. Short-term supports to buy include 6640 (the 20-day MA),...
TECH BIO-TECHNE CORPORATION
RGEN REPLIGEN CORPORATION
REGN REGENERON PHARMACEUTICALS INC.
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
EXAS EXACT SCIENCES CORPORATION
ENS ENERSYS
BIIB BIOGEN INC.
BGNE BEIGENE LTD. SPONSORED ADR
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ALNY ALNYLAM PHARMACEUTICALS INC
IONS IONIS PHARMACEUTICALS INC.
UTHR UNITED THERAPEUTICS CORPORATION
MDGL MADRIGAL PHARMACEUTICALS
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
QS QUANTUMSCAPE
ENVX ENOVIX CORP
FLNC FLUENCE ENERGY INC
SLDP SOLID POWER INC
MVST MICROVAST HLDGS INC
AMPX AMPRIUS TECHNOLOGIES INC
SES SES AI CORPORATION
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
TE ALUSSA ENERGY ACQUISITION CORP
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma and Chairman of the Board. “Ted has extensive resea...
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Compa...
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma’s platform valueInvestments since 2020 on track to deliver mid-teens unlevered IRR, ahead of targetAchieved 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE) since 2019Royalty market continues to ...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma...
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansionRoyalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, ...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Hea...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a ...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured N...
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”);$900 million of 5.200% Notes due 2035 (the “2035 Notes”); and$500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, L...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.